Curaleaf International, a division of Curaleaf Holdings (OTCQX:CURLF) (CSE:CURA), announced the successful license of the company’s range of cannabis based medicines as extract, under the name Adven, in Malta.
The product range is being manufactured to meet the growing demand for medical cannabis products across Europe and builds on Curaleaf International being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient in Italy. The products are already being prescribed to a growing number of patients in the UK and Germany.
